{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:00:03Z","timestamp":1791291603898,"version":"4.3.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[1998,5,1]],"date-time":"1998-05-01T00:00:00Z","timestamp":893980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"vor","delay-in-days":7922,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[1998,5]]},"DOI":"10.1023\/a:1008265313133","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T13:47:34Z","timestamp":1040564854000},"page":"527-534","source":"Crossref","is-referenced-by-count":132,"title":["Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma"],"prefix":"10.1016","volume":"9","author":[{"given":"K.","family":"Tobinai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Narabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Kagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Morishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ohtsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Murate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 5","key":"10.1023\/A:1008265313133_bb0010","first-page":"75","article-title":"Natural history of and therapy for the indolent non-Hodgkin\u2019s lymphomas","volume":"20","author":"Horning","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1008265313133_bb0015","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1200\/JCO.1997.15.2.445","article-title":"High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin\u2019s lymphoma","volume":"15","author":"Bierman","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008265313133_bb0020","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1182\/blood.V65.6.1349.bloodjournal6561349","article-title":"A clinical trial of anti-idiotype therapy for B cell malignancy","volume":"65","author":"Meeker","year":"1985","journal-title":"Blood"},{"key":"10.1023\/A:1008265313133_bb0025","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.4049\/jimmunol.125.4.1678","article-title":"Characterization of a human B lymphocyte-specific antigen","volume":"125","author":"Stashenko","year":"1980","journal-title":"J Immunol"},{"key":"10.1023\/A:1008265313133_bb0030","first-page":"73","article-title":"Cellular origin of human lymphoid malignancies as based on immunologic analysis of membrane differentiation antigens","volume":"12","author":"Tobinai","year":"1982","journal-title":"Jpn J Clin Oncol"},{"key":"10.1023\/A:1008265313133_bb0035","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood.V63.6.1424.1424","article-title":"Expression of human B cell associated antigens on leukemias and lymphomas: A model of human B cell differentiation","volume":"63","author":"Anderson","year":"1984","journal-title":"Blood"},{"key":"10.1023\/A:1008265313133_bb0040","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood.V69.2.584.584","article-title":"Monoclonal antibody IF5 (anti-CD20) serotherapy of human B cell lymphomas","volume":"69","author":"Press","year":"1987","journal-title":"Blood"},{"key":"10.1023\/A:1008265313133_bb0045","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJM199310213291702","article-title":"Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support","volume":"329","author":"Press","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1023\/A:1008265313133_bb0050","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0140-6736(95)92225-3","article-title":"Phase II trial of 1311-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas","volume":"346","author":"Press","year":"1995","journal-title":"Lancet"},{"key":"10.1023\/A:1008265313133_bb0055","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJM199308123290703","article-title":"Radioimmunotherapy of B-cell lymphoma with [131I] anti-B1 (anti-CD20) antibody","volume":"329","author":"Kaminski","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1023\/A:1008265313133_bb0060","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.1996.14.7.1974","article-title":"Iodine-131: Anti-B1 radioimmunotherapy for B-cell lymphoma","volume":"14","author":"Kaminski","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008265313133_bb0065","first-page":"457","article-title":"Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma","volume":"2","author":"Knox","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1023\/A:1008265313133_bb0070","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vitro by chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1023\/A:1008265313133_bb0075","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase 1 clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma","volume":"84","author":"Maloney","year":"1994","journal-title":"Blood"},{"key":"10.1023\/A:1008265313133_bb0080","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin\u2019s lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008265313133_bb0085","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1023\/A:1008265313133_bb0090","first-page":"90a","article-title":"IDEC-C2B8 anti-CD20 antibody: final report on a phase III pivotal trial in patients with relapsed low-grade or follicular lymphoma","volume":"88","author":"McLaughlin","year":"1996","journal-title":"Blood"},{"key":"10.1023\/A:1008265313133_bb0095","first-page":"1215","article-title":"Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen","volume":"136","author":"Mason","year":"1990","journal-title":"Am J Pathol"},{"key":"10.1023\/A:1008265313133_bb0100","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/oxfordjournals.jjco.a039642","article-title":"Toxicity grading criteria of the Japan Clinical Oncology Group","volume":"23","author":"Tobinai","year":"1993","journal-title":"Jpn J Clin Oncol"},{"key":"10.1023\/A:1008265313133_bb0105","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.4049\/jimmunol.124.4.1929","article-title":"Murine antibody-dependent cell-mediated cytotoxicity: Failure to detect effector cells equivalent to human K cells","volume":"124","author":"Tada","year":"1980","journal-title":"J Immunol"},{"key":"10.1023\/A:1008265313133_bb0110","first-page":"83","article-title":"Effects of corticosteroids on natural killer cell activity in systemic lupus erythematosus","volume":"40","author":"Oshimi","year":"1980","journal-title":"Clin Exp Immunol"},{"key":"10.1023\/A:1008265313133_bb0115","series-title":"WHO Handbook for Reporting Results of Cancer Treatment","year":"1979"},{"key":"10.1023\/A:1008265313133_bb0120","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2","article-title":"National Cancer Institute sponsored study of classifications of non-Hodgkin\u2019s lymphomas: Summary and description of a Working Formulation for clinical usage","volume":"49","author":"Non-Hodgkin\u2019s Lymphoma Pathologic Classification Project","year":"1982","journal-title":"Cancer"},{"key":"10.1023\/A:1008265313133_bb0125","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/cbr.1997.12.177","article-title":"Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs","volume":"12","author":"Demidem","year":"1997","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1023\/A:1008265313133_bb0130","first-page":"637a","article-title":"The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin\u2019s lymphoma cell lines","volume":"88","author":"Maloney","year":"1996","journal-title":"Blood"},{"key":"10.1023\/A:1008265313133_bb0135","first-page":"418","article-title":"Pharmacokinetic analysis of serum concentrations of the chimeric anti-CD20 antibody IDEC-C2B8 in patients with relapsed B-cell lymphoma","volume":"15","author":"Rosenberg","year":"1996","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1023\/A:1008265313133_bb0140","first-page":"85","article-title":"IDEC-C2B8 (rituximab) levels correlate with response in low-grade or follicular on-Hodgkin\u2019s lymphoma","volume":"38","author":"Berinstein","year":"1997","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1023\/A:1008265313133_bb0145","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0046-8177(83)80299-8","article-title":"Lymphoproliferative diseases in Japan and western countries","volume":"14","author":"Kadin","year":"1983","journal-title":"Hum Pathol"},{"key":"10.1023\/A:1008265313133_bb0150","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/0277-5379(89)90361-1","article-title":"Non-Hodgkin\u2019s lymphoma of follicular center cell type in Osaka, Japan","volume":"25","author":"Ohsawa","year":"1989","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1023\/A:1008265313133_bb0155","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/oxfordjournals.jjco.a023262","article-title":"Prognostic factors and a predictive model of follicular lymphoma: A 25-year study at a single institution in Japan","volume":"26","author":"Katsumata","year":"1996","journal-title":"Jpn J Clin Oncol"},{"key":"10.1023\/A:1008265313133_bb0160","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/hon.2900070305","article-title":"Malignant lymphoma in Hawaii-Japanese: A retrospective morphologic survey","volume":"7","author":"Yanagihara","year":"1989","journal-title":"Hematol Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419610100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419610100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/9\/5\/527\/19481792\/9-5-527.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T16:42:05Z","timestamp":1682008925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419610100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1998,5]]}},"alternative-id":["S0923753419610100"],"URL":"https:\/\/doi.org\/10.1023\/a:1008265313133","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[1998,5]]}}}